Mirati Therapeutics, Inc. (MRTX) — Financial statements
Income statement, balance sheet, and cash flow for Mirati Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 12↓82.7% | 72↑438.1% | 13↑301.7% | 3↓74.2% | 13 | |
| Cost of Revenue | 0.60↓66.3% | 2↓99.4% | 299↑63.7% | 183↑94.8% | 94 | |
| Gross Profit | 12↑102.7% | -437↓52.6% | -286↓59.3% | -180↓121.8% | -81 | |
| Operating Expenses | ||||||
| R&D Expenses | 532↑4.5% | 509↑69.9% | 299↑63.7% | 183↑94.8% | 94 | |
| General & Administrative Expenses | 0.00↓100.0% | 137↑63.9% | 83↑95.9% | 43↑96.4% | 22 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 240↑75.4% | 137↑63.9% | 83↑95.9% | 43↑96.4% | 22 | |
| Other Expenses | 0.00↑100.0% | -5↓146.4% | 11↑29.1% | 9↑110.2% | 4 | |
| Operating Expenses | 771↑19.6% | 645↑68.6% | 383↑1034.9% | 34↓70.8% | 116 | |
| Total Costs & Expenses | 772↑19.6% | 645↑68.6% | 383↑69.8% | 225↑95.1% | 116 | |
| Operating Results | ||||||
| Operating Income | -760↓32.5% | -573↓55.2% | -369↓66.3% | -222↓116.4% | -103 | |
| Depreciation & Amortization | 3↑64.5% | 2↑177.8% | 0.64↑157.4% | 0.25↑42.3% | 0.18 | |
| EBITDA | -757↓32.4% | -571↓55.0% | -369↓66.2% | -222↓116.2% | -103 | |
| EBIT | -758↓32.3% | -573↓55.2% | -369↓66.3% | -222↓116.4% | -103 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | -1 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | 19↑462.6% | -5↓146.4% | 11↑29.1% | 9↑110.2% | 4 | |
| Income Before Tax | -740↓28.0% | -578↓61.6% | -358↓67.8% | -213↓116.7% | -98 | |
| Income Tax Expense | 0.51↓84.6% | 3↑745.6% | -0.51↑22.5% | -0.66 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -741↓27.3% | -582↓62.8% | -357↓68.1% | -213↓116.0% | -98 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -741↓27.3% | -582↓62.5% | -358↓67.8% | -213↓116.7% | -98 | |
| Bottom-Line Net Income | -741↓27.3% | -582↓62.8% | -357↓68.1% | -213↓116.0% | -98 | |
| EPS (Basic) | -13.18↓17.6% | -11.21↓40.8% | -7.96↓39.9% | -5.69↓78.4% | -3.19 | |
| EPS (Diluted) | -13.18↓17.6% | -11.21↓40.8% | -7.96↓39.9% | -5.69↓78.4% | -3.19 | |
| Weighted Average Shares | 56↑8.4% | 52↑15.3% | 45↑20.1% | 37↑21.3% | 31 | |
| Weighted Average Diluted Shares | 56↑8.4% | 52↑15.3% | 45↑20.1% | 37↑21.3% | 31 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.